A phase 2 trial tested a de-intensified treatment approach using once-weekly erlotinib in familial adenomatous polyposis (FAP) patients. The treatment reduced d..
A phase 1/2 trial showed that combining mevrometostat with enzalutamide significantly extended progression-free survival (PFS) in metastatic castration-resistan..
Cancer cachexia, first defined in 1858, causes significant weight loss in cancer patients and impacts treatment outcomes. Ponsegromab, an antibody against growt..
The 10-year results of the FOWARC trial showed that neoadjuvant modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) with or without radiati..
The EREMISS phase II trial presented at ESMO Congress 2024 showed that regorafenib significantly delayed disease progression in patients with metastatic or loca..
The KEYNOTE-A18 study presented at ESMO 2023 showed that combining pembrolizumab with concurrent chemoradiotherapy (CCRT) significantly improved progression-fre..
The 3-year follow-up results from the CAPTIVATE trial showed that the combination of ibrutinib and venetoclax in treatment-naive chronic lymphocytic leukemia (C..